Phase 1 Clinical Trial Amendment Approved for Nasogastric Administration of Jakubo ODT, Potential Label Expansion Enhances Product Value
[Event] Onconic Therapeutics received approval (2026-06-02 from MFDS) for an amendment to a Phase 1 clinical trial to evaluate nasogastric tube administration of its already marketed drug Jakubo ODT (Zastaprazan).
[Rationale] To assess pharmacokinetics and safety of nasogastric administration in patients who cannot take oral medication (e.g., ICU patients), aiming to expand the drug's labeled administration route.
[Trial Design] Open-label, randomized, single-dose, crossover, fasting study in 48 healthy volunteers. Bioequivalence (Cmax, AUCt) between oral and nasogastric routes will be tested using 90% CI within log 0.8–1.25.
[Expected Impact] If successful, the label expansion could allow use in new patient populations, potentially increasing sales. The drug is already approved, so this is a value-enhancing step with limited downside risk.
[Risks] Phase 1 has low statistical success (around 10%), but failure would not affect existing business significantly since the drug is already marketed.
[Stock Outlook] Near-term catalyst is limited, but long-term value may rise if label expansion leads to market expansion.
[AI Summary]The Phase 1 approval for route expansion of an already approved drug is positive for product value, though success probability is low. Limited short-term price impact, but strategic potential for revenue growth.
KOSDAQ Filing Information
Filing: Major Management Matters Related To Investment Decision (Clinical Trial Plan Change Approval) (Phase 1 Clinical Trial Plan Approval (Amendment Approval) For Comparative Evaluation Of Pharmacokinetics And Safety Of Jakubo Orally Disintegrating Tablet (JLP-2302) Via Nasogastric Tube Administration)